Citations

Citations to this article as recorded by  

• Unravelling the molecular mechanisms causal to type 2 diabetes across global populations and disease-relevant tissues
  Ozvan Bocher, Ana Luiza Arruda, Satoshi Yoshiji, Chi Zhao, Alicia Huerta-Chagoya, Chen-Yang Su, Xianyong Yin, Davis Cammann, Henry J. Taylor, Jingchun Chen, Ken Suzuki, Ravi Mandla, Ta-Yu Yang, Fumihiko Matsuda, Josep M. Mercader, Jason Flannick, James B.
  Nature Metabolism.2026; 8(2): 506.     CrossRef

Citations

Citations to this article as recorded by  

• Plasminogen activator inhibitor-1, vaspin, and dietary inflammatory index in relation to cardiometabolic health in diabetic women
  Sule Kocabas, Nevin Sanlier
  Frontiers in Nutrition.2026;[Epub]     CrossRef
• The Relationship Between High-Density Lipoprotein (HDL) and Glycated Hemoglobin (HbA1C) in Type 2 Diabetes Mellitus Patients: Implications for Cardiovascular Risk
  Setyoadi Setyoadi, Dina Dewi Sartika Lestari Ismail, Annisa Wuri Kartika, Dewi Purnama Sari, Angel Dwi Septian, Adelina Stefanie Lallo, Rara Kurniasari
  Journal of Rural Community Nursing Practice.2025; 3(2): 234.     CrossRef

The prevalence of obesity in Asia is of epidemic proportions, with an estimated 1 billion overweight/obese individuals in the region. The majority of patients with type 2 diabetes mellitus (T2DM) are overweight/obese, which increases the risk of cardiorenal outcomes in these patients; hence, sustained reductions in body weight and visceral adiposity are important management goals. However, most of the glucose-lowering therapies such as insulin, sulfonylureas, glinides, and thiazolidinediones induce weight gain, which makes the management of overweight/obese T2DM patients challenging. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are the only oral glucose-lowering agents that have been shown to reduce body weight and visceral adiposity. In addition, SGLT-2 inhibitors therapy reduces ectopic fat deposition and improves adipose tissue function and weight-related quality of life. In this article, we aim to consolidate the existing literature on the effects of SGLT-2 inhibitors in Asian patients with T2DM and to produce clinical recommendations on their use in overweight or obese patients with T2DM. Recommendations from international and regional guidelines, as well as published data from clinical trials in Asian populations and cardiovascular outcomes trials are reviewed. Based on the available data, SGLT-2 inhibitors represent an evidence-based therapeutic option for the management of overweight/obese patients with T2DM.

Citations

Citations to this article as recorded by  

• Risk of depression with GLP‐1 receptor agonists use in overweight or obese adults with type 2 diabetes: A new‐user, active‐comparator cohort study
  Yu Chang, Ming‐Hong Hsieh, Po‐Chung Ju, Cheng‐Chen Chang
  Diabetes, Obesity and Metabolism.2026; 28(1): 197.     CrossRef
• Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial
  Jun Hwa Hong, Kyung Ah Han, You-Cheol Hwang, Eun-Gyoung Hong, Hae Jin Kim, Chang Beom Lee, Ho Chan Cho, Jong Chul Won, Hun-Sung Kim, Eui-Hyun Kim, Gwanpyo Koh, Kwang Hyun Ahn, Kyong Soo Park
  Diabetes & Metabolism Journal.2026; 50(2): 320.     CrossRef
• Hypothesis: Nutrient Off-Loading and Ectopic Fat Reduction Reverse Insulin Resistance and Improve Cardiovascular Outcomes in Type 2 Diabetes—A Narrative Review
  Joseph A. M. J. L. Janssen
  International Journal of Molecular Sciences.2026; 27(5): 2150.     CrossRef
• SGLT-2i—A Useful Tool for Real-Life Metabolic and Body Weight Control in Type 2 Diabetes Mellitus Patients
  Mihaela-Simona Popoviciu, Teodor Salmen, Delia Reurean-Pintilei, Vlad Voiculescu, Anca Pantea Stoian
  Medicina.2025; 61(3): 548.     CrossRef
• Discrepancies in Dapagliflozin Response in Terms of Glycemic Control and Body Weight Reduction
  Ji Eun Jun, Kyoung-Ah Kim, Nan-Hee Kim, Kwan-Woo Lee, In-Kyung Jeong
  Endocrinology and Metabolism.2025; 40(2): 278.     CrossRef
• Efficacy and safety of pioglitazone, empagliflozin and glimepiride as third‐line agents in patients with type 2 diabetes inadequately controlled with metformin and DPP‐4 inhibitors: A multicentre, phase 4 randomized controlled trial
  Yun Kyung Cho, Jae‐Hyoung Cho, Sang‐Mo Hong, Jung Hwan Park, Byung‐Wan Lee, Jee Hee Yoo, Jae Hyeon Kim, Sung Wan Chun, You‐Cheol Hwang, Kee‐Ho Song, Woo Je Lee
  Diabetes, Obesity and Metabolism.2025; 27(11): 6375.     CrossRef
• Indian Clinicians’ Perspectives on Utilizing Dapagliflozin-Based Combination Therapy for the Management of Obesity in Patients With Type 2 Diabetes Mellitus
  Mayur Agrawal, Abhay Ahluwalia, Raman Boddula, Arjun Baidya, Hiteswar Saikia, Anu Mathew, Prem Naryanan, Arjun R, Modhugu N Reddy, Rohan N Kesarkar, Abhijit Pednekar
  Cureus.2025;[Epub]     CrossRef
• New approach to optimize therapy in type 2 diabetes mellitus: the importance of subclassification
  María José Reyes-Medina, Vanesa Cantón-Habas, Francisco Javier Sánchez-Jiménez, Enrique Molina-Hurtado, María del Pilar Carrera-González
  Frontiers in Endocrinology.2025;[Epub]     CrossRef
• Comparative efficacy of multiple drugs for non-alcoholic fatty liver disease: a Bayesian network meta-analysis
  Zhile Xiao, Xiaonan Li, Jiahong Gong, Feng Zhou
  European Journal of Medical Research.2025;[Epub]     CrossRef
• Extracellular vesicle miR-425-5p promotes visceral fat reduction via DACT1 suppression in SGLT2i-treated diabetes
  Jae-Hyung Park, Thi Nhi Nguyen, Hye Min Shim, Yun-Ui Bae, Gyeong Im Yu, Junho Kang, Eun Yeong Ha, Hochan Cho
  Frontiers in Endocrinology.2025;[Epub]     CrossRef
• The interaction between non-coding RNAs and SGLT2: A review
  Joanna Jarosz-Popek, Ceren Eyileten, Gloria M. Gager, Anna Nowak, Piotr Szwed, Zofia Wicik, Jeff Palatini, Dirk von Lewinski, Harald Sourij, Jolanta M. Siller-Matula, Marek Postula
  International Journal of Cardiology.2024; 398: 131419.     CrossRef
• A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: ENHANCE‐M extension study
  Tae Seo Sohn, Kyung‐Ah Han, Yonghyun Kim, Byung‐Wan Lee, Suk Chon, In‐Kyung Jeong, Eun‐Gyoung Hong, Jang Won Son, JaeJin Na, Jae Min Cho, Seong In Cho, Wan Huh, Kun‐Ho Yoon
  Diabetes, Obesity and Metabolism.2024; 26(6): 2248.     CrossRef
• Comparison of the effects of empagliflozin and sitagliptin, as add-on to metformin, on serum levels of asprosin and metabolic parameters in patients with type 2 diabetes mellitus
  Seyed Saman Talebi, Shabnam Rezaie, Minoo Sadat Hajmiri, Maryam Zamanirafe, Akram Ranjbar, Heresh Moridi, Mahtabalsadat Mirjalili, Maryam Mehrpooya
  Naunyn-Schmiedeberg's Archives of Pharmacology.2024; 397(11): 9149.     CrossRef
• Long‐term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52‐week extension of a Phase 3 randomized controlled trial
  Soo Heon Kwak, Kyung Ah Han, Eun Sook Kim, Sung Hee Choi, Jong Chul Won, Jae Myung Yu, Seungjoon Oh, Hye Jin Yoo, Chong Hwa Kim, Kyung‐Soo Kim, SungWan Chun, Yong Hyun Kim, Seung Ah Cho, Da Hye Kim, Kyong Soo Park
  Diabetes, Obesity and Metabolism.2024; 26(10): 4203.     CrossRef
• Glucose-Lowering Agents Developed in the Last Two Decades and Their Perioperative Implications
  Basavana Goudra, Geno J. Merli, Michael Green
  Pharmaceuticals.2024; 18(1): 4.     CrossRef
• The effect of combining nutrient intake and physical activity levels on central obesity, sarcopenia, and sarcopenic obesity: a population-based cross-sectional study in South Korea
  Jong Eun Park, Seulgi Lee, Kirang Kim
  BMC Geriatrics.2023;[Epub]     CrossRef
• Increased risk of incident diabetes after therapy with immune checkpoint inhibitor compared with conventional chemotherapy: A longitudinal trajectory analysis using a tertiary care hospital database
  Minyoung Lee, Kyeongseob Jeong, Yu Rang Park, Yumie Rhee
  Metabolism.2023; 138: 155311.     CrossRef
• Efficacy and safety of janagliflozin as add‐on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial
  Leili Gao, Zhifeng Cheng, Benli Su, Xiuhai Su, Weihong Song, Yushan Guo, Lin Liao, Xiaowen Chen, Jiarui Li, Xingrong Tan, Fangjiang Xu, Shuguang Pang, Kun Wang, Jun Ye, Yuan Wang, Lili Chen, Jingfang Sun, Linong Ji
  Diabetes, Obesity and Metabolism.2023; 25(3): 785.     CrossRef
• Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
  Bains Jasleen, Gupta K Vishal, Malepati Sameera, Molla Fahad, O'Brien Brendan, Santander Deion, Sudhakar Pemminati
  Cureus.2023;[Epub]     CrossRef
• Safety and Effectiveness of Empagliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results from a Nationwide Post-Marketing Surveillance
  Jun Sung Moon, Nam Hoon Kim, Jin Oh Na, Jae Hyoung Cho, In-Kyung Jeong, Soon Hee Lee, Ji-Oh Mok, Nan Hee Kim, Dong Jin Chung, Jinhong Cho, Dong Woo Lee, Sun Woo Lee, Kyu Chang Won
  Diabetes & Metabolism Journal.2023; 47(1): 82.     CrossRef
• Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity
  Linong Ji, Jie Liu, Zhi Jin Xu, Zhiqi Wei, Ruya Zhang, Seema Malkani, Nilo B. Cater, Robert Frederich
  Diabetes Therapy.2023; 14(2): 319.     CrossRef
• Research Progress of Dapagliflozin in Treatment of Acute Myocardial Infarction Complicated with Type 2 Diabetes Mellitus
  鸿 王
  Advances in Clinical Medicine.2023; 13(02): 1667.     CrossRef
• Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis
  Hye Jin Chun, Eun Ran Kim, Minyoung Lee, Da Hyun Choi, Soo Hyun Kim, Eugene Shin, Jin-Hong Kim, Jin Won Cho, Dai Hoon Han, Bong-Soo Cha, Yong-ho Lee
  Metabolism.2023; 145: 155612.     CrossRef
• Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial
  Kyung Ah Han, Yong Hyun Kim, Doo Man Kim, Byung Wan Lee, Suk Chon, Tae Seo Sohn, In Kyung Jeong, Eun-Gyoung Hong, Jang Won Son, Jae Jin Nah, Hwa Rang Song, Seong In Cho, Seung-Ah Cho, Kun Ho Yoon
  Diabetes & Metabolism Journal.2023; 47(6): 796.     CrossRef
• Renoprotection with sodium‐glucose cotransporter‐2 inhibitors in children: Knowns and unknowns
  Buchun Jiang, Zhiwen Cheng, Fei Liu, Qiuyu Li, Haidong Fu, Jianhua Mao
  Nephrology.2022; 27(2): 126.     CrossRef
• Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis
  Angelo Cignarelli, Valentina Annamaria Genchi, Giulia Le Grazie, Irene Caruso, Nicola Marrano, Giuseppina Biondi, Rossella D’Oria, Gian Pio Sorice, Annalisa Natalicchio, Sebastio Perrini, Luigi Laviola, Francesco Giorgino
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• Sodium–glucose cotransporter 2 inhibitors do not increase the risk of fractures in real‐world clinical practice in Korea: A national observational cohort study
  Kyoung Hwa Ha, Dae Jung Kim, Yong Jun Choi
  Journal of Diabetes Investigation.2022; 13(6): 986.     CrossRef
• Liraglutide Alleviates Diabetic Atherosclerosis through Regulating Calcification of Vascular Smooth Muscle Cells
  Li-Li Shi, Ming Hao, Zhou-Yun Jin, Gui-Fang Peng, Ying-Ying Tang, Hong-Yu Kuang, Yaoyao Bian
  Disease Markers.2022; 2022: 1.     CrossRef
• Relationship Between Four Non-Insulin-Based Indexes of Insulin Resistance and Serum Uric Acid in Patients with Type 2 Diabetes: A Cross-Sectional Study
  Rongfeng Han, Yang Zhang, Xia Jiang
  Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 1461.     CrossRef
• The dual role of empagliflozin: Cardio renal protection in T2DM patients
  Aimen Shafiq, Eman Mahboob, Muhammad Ammar Samad, Mohammad Hassam Ur Rehman, Zoaib Habib Tharwani
  Annals of Medicine & Surgery.2022;[Epub]     CrossRef
• Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?
  Katarzyna Wołos-Kłosowicz, Wojciech Matuszewski, Joanna Rutkowska, Katarzyna Krankowska, Elżbieta Bandurska-Stankiewicz
  Journal of Clinical Medicine.2022; 11(20): 6183.     CrossRef
• Tackling type 2 diabetes-associated cardiovascular and renal comorbidities: a key challenge for drug development
  Ernest A. Adeghate, Huba Kalász, Saeeda Al Jaberi, Jennifer Adeghate, Kornelia Tekes
  Expert Opinion on Investigational Drugs.2021; 30(2): 85.     CrossRef
• Henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial
  Jianping Weng, Longyi Zeng, Yuwei Zhang, Shen Qu, Xueying Wang, Ping Li, Liujun Fu, Boqing Ma, Shandong Ye, Jiao Sun, Weiping Lu, Zhiwen Liu, Daoxiong Chen, Zhifeng Cheng, Haiyan Liu, Tao Zhang, Jianjun Zou
  Diabetes, Obesity and Metabolism.2021; 23(8): 1754.     CrossRef
• How do you treat obesity in the elderly pharmacologically?
  Claudio Daniel González, Guillermo Di Girolamo
  Expert Opinion on Pharmacotherapy.2021; 22(13): 1639.     CrossRef
• Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy
  Ayako Nagayama, Kenji Ashida, Miki Watanabe, Kanoko Moritaka, Aya Sonezaki, Yoichiro Kitajima, Hirokazu Takahashi, Satoko Yoshinobu, Shimpei Iwata, Junichi Yasuda, Nao Hasuzawa, Shuichi Ozono, Seiichi Motomura, Masatoshi Nomura
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• New Pandemic: Obesity and Associated Nephropathy
  Isha Sharma, Yingjun Liao, Xiaoping Zheng, Yashpal S. Kanwar
  Frontiers in Medicine.2021;[Epub]     CrossRef
• Novel strategies for glycaemic control and preventing diabetic complications applying the clustering-based classification of adult-onset diabetes mellitus: A perspective
  Hayato Tanabe, Hiroaki Masuzaki, Michio Shimabukuro
  Diabetes Research and Clinical Practice.2021; 180: 109067.     CrossRef
• The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients
  Mariana Tilinca, Robert Tiuca, Ioan Tilea, Andreea Varga
  Journal of Personalized Medicine.2021; 11(12): 1249.     CrossRef
• The ‘diamond’ approach to personalized drug treatment of heart failure with reduced ejection fraction
  Hongbo Gan, Heng Tang, Yujie Huang, Dan Wang, Peng Pu, Zhong Zuo
  Reviews in Cardiovascular Medicine.2021;[Epub]     CrossRef
• Lowering the risk of gout: Another benefits from the use of sodium–glucose cotransporter 2 inhibitors
  Wayne H‐H Sheu
  Journal of Diabetes Investigation.2020; 11(5): 1115.     CrossRef

• SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients

  
  André J Scheen
  Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 2765.     CrossRef
• SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
  Yoshifumi Saisho
  Diseases.2020; 8(2): 14.     CrossRef
• Roles of Epicardial Adipose Tissue in the Pathogenesis of Coronary Atherosclerosis　― An Update on Recent Findings ―
  Kimie Tanaka, Daiju Fukuda, Masataka Sata
  Circulation Journal.2020; 85(1): 2.     CrossRef